BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 23130931)

  • 1. Update on thyroid cancer treatment.
    Regalbuto C; Frasca F; Pellegriti G; Malandrino P; Marturano I; Di Carlo I; Pezzino V
    Future Oncol; 2012 Oct; 8(10):1331-48. PubMed ID: 23130931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target therapies for radioiodine refractory advanced thyroid tumors.
    Schlumberger M
    J Endocrinol Invest; 2012; 35(6 Suppl):40-4. PubMed ID: 23014073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy in radioiodine refractory thyroid cancer.
    Pacini F; Brilli L; Marchisotta S
    Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):520-5. PubMed ID: 19910905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular targeted therapies for patients with refractory thyroid cancer.
    Chougnet C; Brassard M; Leboulleux S; Baudin E; Schlumberger M
    Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):448-55. PubMed ID: 20554167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New molecular targeted therapies in thyroid cancer.
    Milano A; Chiofalo MG; Basile M; Salzano de Luna A; Pezzullo L; Caponigro F
    Anticancer Drugs; 2006 Sep; 17(8):869-79. PubMed ID: 16940797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era.
    Capdevila J; Argiles G; Rodriguez-Frexinos V; Nuñez I; Tabernero J
    Discov Med; 2010 Feb; 9(45):153-62. PubMed ID: 20193642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy: a new hope for thyroid carcinomas.
    Perri F; Pezzullo L; Chiofalo MG; Lastoria S; Di Gennaro F; Scarpati GD; Caponigro F
    Crit Rev Oncol Hematol; 2015 Apr; 94(1):55-63. PubMed ID: 25465739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets.
    Spitzweg C; Bible KC; Hofbauer LC; Morris JC
    Lancet Diabetes Endocrinol; 2014 Oct; 2(10):830-42. PubMed ID: 24898835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Therapy in Thyroid Cancer: State of the Art.
    Valerio L; Pieruzzi L; Giani C; Agate L; Bottici V; Lorusso L; Cappagli V; Puleo L; Matrone A; Viola D; Romei C; Ciampi R; Molinaro E; Elisei R
    Clin Oncol (R Coll Radiol); 2017 May; 29(5):316-324. PubMed ID: 28318881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The current role of targeted therapies to induce radioiodine uptake in thyroid cancer.
    Fröhlich E; Wahl R
    Cancer Treat Rev; 2014 Jun; 40(5):665-74. PubMed ID: 24485648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redifferentiating agents in non-radioiodine avid cancer.
    Seregni E; Vellani C; Castellani MR; Maccauro M; Pallotti F; Scaramellini G; Guzzo M; Greco A
    Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):513-9. PubMed ID: 19910904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
    Shen CT; Qiu ZL; Luo QY
    Endocr Relat Cancer; 2014 Apr; 21(2):253-61. PubMed ID: 24302666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging therapies for thyroid carcinoma.
    Walsh S; Prichard R; Hill AD
    Surgeon; 2012 Feb; 10(1):53-8. PubMed ID: 22233555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioiodine therapy for thyroid cancer in the era of risk stratification and alternative targeted therapies.
    Pryma DA; Mandel SJ
    J Nucl Med; 2014 Sep; 55(9):1485-91. PubMed ID: 25134528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted treatments of radio-iodine refractory differentiated thyroid cancer.
    de la Fouchardière C
    Ann Endocrinol (Paris); 2015 Feb; 76(1 Suppl 1):1S34-9. PubMed ID: 26826481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapy in thyroid cancer.
    Nixon IJ; Shaha AR; Tuttle MR
    Curr Opin Otolaryngol Head Neck Surg; 2013 Apr; 21(2):130-4. PubMed ID: 23435040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic options in papillary thyroid carcinoma: current guidelines and future perspectives.
    Scott E; Learoyd D; Clifton-Bligh RJ
    Future Oncol; 2016 Nov; 12(22):2603-2613. PubMed ID: 27387641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on clinical trials of targeted therapies in thyroid cancer.
    Haraldsdottir S; Shah MH
    Curr Opin Oncol; 2014 Jan; 26(1):36-44. PubMed ID: 24240178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Use of new molecules in the treatment of advanced thyroid cancer].
    Galofré JC; Gómez-Sáez JM; Álvarez Escola C; Álvarez García E; Anda Apiñaniz E; Calleja A; Donnay S; Lucas-Martin A; Menéndez Torre E; Navarro González E; Pereg V; Pérez Corral B; Santamaría Sandi J; Riesco Eizaguirre G; Zafón Llopis C;
    Endocrinol Nutr; 2011 Oct; 58(8):381-6. PubMed ID: 21924966
    [No Abstract]   [Full Text] [Related]  

  • 20. Update on recent developments in the therapy of differentiated thyroid cancer.
    Middendorp M; Grünwald F
    Semin Nucl Med; 2010 Mar; 40(2):145-52. PubMed ID: 20113682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.